LOW-DOSE FLUVOXAMINE TREATMENT OF CHILDREN AND ADOLESCENTS WITH PERVASIVE DEVELOPMENTAL DISORDERS: A PROSPECTIVE, OPEN-LABEL STUDY
Zapisane w:
MARTIN, A., ET AL., LOW-DOSE FLUVOXAMINE TREATMENT OF CHILDREN AND ADOLESCENTS WITH PERVASIVE DEVELOPMENTAL DISORDERS: A PROSPECTIVE, OPEN-LABEL STUDY. JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, Vol. 33, no. 1 (2003), p. 77-85.
Ref.
119655
Lokalizacja:
SIIS R.237 Archivo
Palabras clave:
Autismo, Discapacidad intelectual, Fármacos, Síndrome de Asperger, Trastornos de la conducta, Trastornos del espectro autista, Tratamiento médico
Autismo, Discapacidad intelectual, Fármacos, Síndrome de Asperger, Trastornos de la conducta, Trastornos del espectro autista, Tratamiento médico
Podobne zapisy: LOW-DOSE FLUVOXAMINE TREATMENT OF CHILDREN AND ADOLESCENTS WITH PERVASIVE DEVELOPMENTAL DISORDERS: A PROSPECTIVE, OPEN-LABEL STUDY
- COHESIVE DISCOURSE IN PERVASIVE DEVELOPMENTAL DISORDERS
- FAMILIAR FACTORS INFLUENCE LEVEL OF FUNCTIONING IN PERVASIVE DEVELOPMENTAL DISORDER
- EARLY SYMPTOMS AND RECOGNITION OF PERVASIVE DEVELOPMENTAL DISORDERS IN GERMANY
- HIGHER-FUNCTIONING PERVASIVE DEVELOPMENTAL DISORDERS: RATES AND PATTERNS OF PSYCHOTROPIC DRUG USE
- RELIABILITY AND ACCURACY OF DIFFERENTIATING PERVASIVE DEVELOPMENTAL DISORDER SUBTYPES
- IS AUTISM A PERVASIVE DEVELOPMENTAL DISORDER? DEBATE AND ARGUMENT: HOW USEFUL IS THE "PDD" LABEL?